Document:

Second Amendment to Senior Revolving Credit Agreement

 Exhibit 10.1 
 Execution Version 
 SECOND AMENDMENT 

TO 

SENIOR REVOLVING CREDIT AGREEMENT 
 DATED AS OF JANUARY 25, 2013 
 AMONG 

HALCÓN RESOURCES CORPORATION, 
 AS BORROWER, 
 THE GUARANTORS, 

JPMORGAN CHASE BANK, N.A., 
 AS ADMINISTRATIVE AGENT, 
 WELLS FARGO BANK, N.A. 

AS SYNDICATION AGENT, 
 BANK OF MONTREAL, 
 AS DOCUMENTATION AGENT, 

AND 

THE LENDERS PARTY HERETO 
 SOLE LEAD ARRANGER 
 J. P. MORGAN SECURITIES LLC 

JOINT BOOKRUNNERS 
 J. P. MORGAN SECURITIES LLC AND WELLS FARGO SECURITIES, LLC 
  

 SECOND AMENDMENT 

TO SENIOR REVOLVING CREDIT AGREEMENT 
 THIS SECOND AMENDMENT TO SENIOR REVOLVING CREDIT AGREEMENT (this “Second Amendment”) dated as of January 25, 2013 is among HALCÓN RESOURCES CORPORATION, a
corporation duly formed and existing under the laws of the State of Delaware (the “Borrower”), each of the undersigned guarantors (the “Guarantors”, and together with the Borrower, the “Obligors”),
each of the lenders party to the Credit Agreement referred to below (collectively, the “Lenders”), JPMORGAN CHASE BANK, N.A., as administrative agent for the Lenders (in such capacity, together with its successors in such
capacity, the “Administrative Agent”), Wells Fargo Bank, N.A., as syndication agent for the Lenders and Bank of Montreal, as documentation agent for the Lenders. 

R E C I T A L S 
 A. The Borrower, the Administrative Agent, the Lenders and the other Agents party thereto, are parties to that certain Senior Revolving Credit Agreement dated as of February 8, 2012 as amended by the
First Amendment dated July 31, 2012 (as amended, restated, modified or supplemented, the “Credit Agreement”), pursuant to which the Lenders have made certain credit and other financial accommodations available to and on behalf
of the Borrower and its Subsidiaries. 
 B. The Borrower has requested and the Administrative Agent and the Majority Lenders
have agreed to amend certain provisions of the Credit Agreement. 
 C. NOW, THEREFORE, to induce the Administrative Agent and
the Lenders to enter into this Second Amendment and in consideration of the premises and the mutual covenants herein contained, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 
 Section 1. Defined Terms. Each capitalized term used herein but not otherwise defined herein has the meaning
given such term in the Credit Agreement, as amended by this Second Amendment. Unless otherwise indicated, all section references in this Second Amendment refer to sections of the Credit Agreement. 

Section 2. Amendments to Credit Agreement. 
 2.1 Amendments to Section 1.02. Section 1.02 is hereby amended by: 

(a) Deleting the definitions of “Agreement” in its entirety and replacing each with the following: 

“Agreement” means this Senior Revolving Credit Agreement, as amended by the First Amendment dated July 31, 2012 and
the Second Amendment dated January 25, 2013, as the same may be amended or supplemented from time to time. 

 (b) Adding the following defined terms in the appropriate alphabetical order: 

“Projected Production” means, as of any date of determination, the internally forecasted production of each of crude oil,
natural gas liquids and natural gas, calculated on a barrel of oil equivalent basis, of the Borrower and its Restricted Subsidiaries, or in the case of a Proposed Acquisition, from the Oil and Gas Properties subject of such Proposed Acquisition, for
each month for the period of the next 24 months commencing on the first day of the calendar month immediately following such date of determination. 
 “Proposed Acquisition” has the meaning assigned such term in Section 9.19(c). 
 (c) Deleting the defined term “Current Production”. 
 2.2 Amendments to
Section 9.19. Section 9.19 is hereby amended by deleting such Section in its entirety and replacing it with the following: 
 “Section 9.19 Swap Agreements. The Borrower will not, and will not permit any Restricted Subsidiary to, enter into any Swap Agreements with any Person other than: 

(a) Swap Agreements in respect of commodities (i) with an Approved Counterparty and (ii) the notional volumes for which (when
aggregated with other commodity Swap Agreements then in effect, other than puts, floors and basis differential swaps on volumes already hedged pursuant to other Swap Agreements) do not exceed, as of the date such Swap Agreement is executed,
(A) 85% of the Projected Production for each month during the period during which such Swap Agreement is in effect for crude oil, natural gas liquids and natural gas, for the period of 24 months following the date such Swap Agreement is
executed and (B) 85% of the reasonably anticipated Hydrocarbon production from the total Proved Reserves of the Borrower and its Restricted Subsidiaries (as forecast based upon the most recently delivered Reserve Report), each month during the
period during which such Swap Agreement is in effect for crude oil, natural gas liquids and natural gas, calculated on a barrel of oil equivalent basis, for the period of 25 to 66 months following the date such Swap Agreement is executed.

 (b) Swap Agreements in respect of interest rates with an Approved Counterparty, as follows: (i) Swap Agreements
effectively converting interest rates from fixed to floating, the notional amounts of which (when aggregated and netted with all other Swap Agreements of the Borrower and its Restricted Subsidiaries then in effect effectively converting interest
rates from fixed to floating) do not exceed 50% of the then outstanding principal amount of the Borrower’s Debt for borrowed money which bears interest at a fixed rate and (ii) Swap Agreements

  
 2 

 
effectively converting interest rates from floating to fixed, the notional amounts of which (when aggregated and netted with all other Swap Agreements of the Borrower and its Restricted
Subsidiaries then in effect effectively converting interest rates from floating to fixed) do not exceed 75% of the then outstanding principal amount of the Borrower’s Debt for borrowed money which bears interest at a floating rate. In no event
shall any Swap Agreement contain any requirement, agreement or covenant for the Borrower or any Restricted Subsidiary to post collateral or margin to secure their obligations under such Swap Agreement or to cover market exposures except to the
extent permitted by Section 9.03(d). 
 (c) In addition to Swap Agreements under Section 9.19(a)
and without further limitation, in connection with a proposed acquisition of Oil and Gas Properties or Equity Interests of a Person owning Oil and Gas Properties (a “Proposed Acquisition”), the Borrower or any Restricted Subsidiary
may also enter into incremental Swap Agreements with respect to the reasonably anticipated projected production from the Oil and Gas Properties subject of the Proposed Acquisition so long as (i) the Borrower or a Restricted Subsidiary has
signed a definitive acquisition agreement in connection with a Proposed Acquisition and (ii) the aggregate notional volumes associated with such incremental Swap Agreements do not exceed (A) 85% of the Projected Production associated with
the Oil and Gas Properties subject of such Proposed Acquisition for each month during the period during which each such Swap Agreement is in effect, for each of crude oil, natural gas liquids and natural gas, calculated on a barrel of oil equivalent
basis, for the period of 24 months following the date such incremental Swap Agreement is executed and (B) 85% of the reasonably anticipated Hydrocarbon production from the total Proved Reserves associated with the Oil and Gas Properties subject
of such Proposed Acquisition (as forecast based upon the reserve report for the Oil and Gas Properties subject of such Proposed Acquisition which has been delivered to the Lenders) for each month during the period during which each such Swap
Agreement is in effect, for each of crude oil, natural gas liquids and natural gas, calculated on a barrel of oil equivalent basis, for the period of 25 to 48 months following the date such incremental Swap Agreement is executed. The Borrower may
permit such incremental Swap Agreements to remain in place so long as none of the following has occurred: (1) undrawn availability during the period prior to the completion or termination of such acquisition has been reduced to less than 10% of
the then effective Borrowing Base, (2) the thirtieth (30th) day after such acquisition has terminated has passed or (3) the 120th day after such definitive acquisition agreement was executed has passed and the acquisition has not been consummated. If
such incremental Swap Agreements are not permitted to remain in place pursuant to the preceding sentence, the Borrower shall promptly terminate or unwind such Swap Agreements. 

  
 3 

 Section 3. Conditions Precedent. The provisions of this Second Amendment shall become effective
on the date when each of the following conditions is satisfied (or waived in accordance with Section 12.02 of the Credit Agreement) (such date, the “Second Amendment Effective Date”): 

3.1 The Administrative Agent shall have received a counterpart of this Second Amendment signed by the Borrower, the Guarantors and the
Lenders constituting the Majority Lenders. 
 3.2 The Administrative Agent shall have received (a) all fees and other
amounts due and payable on or prior to the Second Amendment Effective Date and (b) to the extent invoiced, reimbursement or payment of all out-of-pocket expenses required to be reimbursed or paid by the Borrower under the Credit Agreement.

 3.3 No Default or Event of Default shall have occurred and be continuing as of the date hereof, after giving effect to the
terms of this Second Amendment. 
 The Administrative Agent is hereby authorized and directed to declare this Second Amendment
to be effective when it has received documents confirming or certifying, to the satisfaction of the Administrative Agent, compliance with the conditions set forth in this Section 3 or the waiver of such conditions as permitted in
Section 12.02 of the Credit Agreement. Such declaration shall be final, conclusive and binding upon all parties to the Credit Agreement for all purposes. 
 Section 4. Miscellaneous. 
 4.1 Confirmation. The provisions of
the Credit Agreement, as amended by this Second Amendment, shall remain in full force and effect following the effectiveness of this Second Amendment. 
 4.2 Ratification and Affirmation; Representations and Warranties. Each Obligor hereby (a) acknowledges the terms of this Second Amendment; (b) ratifies and affirms its obligations under,
and acknowledges, renews and extends its continued liability under, each Loan Document to which it is a party and agrees that each Loan Document to which it is a party remains in full force and effect, except as expressly amended hereby, and
(c) represents and warrants to the Lenders that as of the date hereof, after giving effect to the terms of this Second Amendment: (i) all of the representations and warranties contained in each Loan Document to which it is a party are true
and correct in all material respects (except those which have a materiality qualifier, which shall be true and correct as so qualified), except to the extent any such representations and warranties are expressly limited to an earlier date, in which
case, such representations and warranties shall continue to be true and correct as of such specified earlier date; (ii) no Default or Event of Default has occurred and is continuing and (iii) no event or events have occurred which
individually or in the aggregate could reasonably be expected to have a Material Adverse Effect. 
 4.3 Loan Document.
This Second Amendment is a Loan Document. 

  
 4 

 4.4 Counterparts. This Second Amendment may be executed by one or more of the parties
hereto in any number of separate counterparts, and all of such counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of this Second Amendment by facsimile or electronic transmission in portable document
format (.pdf) shall be effective as delivery of a manually executed counterpart hereof. 
 4.5 NO ORAL AGREEMENT. THIS
SECOND AMENDMENT, THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS EXECUTED IN CONNECTION HEREWITH AND THEREWITH REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR UNWRITTEN ORAL
AGREEMENTS OF THE PARTIES. THERE ARE NO ORAL AGREEMENTS BETWEEN THE PARTIES. 
 4.6 GOVERNING LAW. THIS SECOND AMENDMENT
SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF TEXAS. 
 4.7 Payment of Expenses. In
accordance with Section 12.03, the Borrower agrees to pay or reimburse the Administrative Agent for all of its reasonable out-of- pocket costs and reasonable expenses incurred in connection with this Second Amendment, any other documents
prepared in connection herewith and the transactions contemplated hereby, including, without limitation, the reasonable fees and disbursements of counsel to the Administrative Agent 

4.8 Severability. Any provision of this Second Amendment which is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction. 
 4.9 Successors and Assigns. This Second Amendment shall be
binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 
 [SIGNATURES BEGIN
NEXT PAGE] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to be duly executed
as of the date first written above. 
  

							
	BORROWER:	 	HALCÓN RESOURCES CORPORATION
			
		 	By:	 	 /s/ Mark J. Mize

		 		 	Name:	 	Mark J. Mize
		 		 	Title:	 	Executive Vice President, Chief Financial Officer and Treasurer
		
	GUARANTORS:	 	HALCÓN HOLDINGS, INC.
		 	HALCÓN RESOURCES OPERATING, INC.
		 	HALCÓN ENERGY PROPERTIES, INC.
		 	HLP GULF STATES, LLC
		 	GREAT PLAINS PIPELINE COMPANY
		 	HALCÓN OPERATING CO., INC.
		 	HRC ENERGY RESOURCES (WV), INC.
		 	HRC ENERGY HOLDINGS (LA), INC.
		 	 HRC ENERGY LOUISIANA, LLC
 HALCON GEO HOLDINGS, LLC

		 	PONTOTOC PRODUCTION COMPANY, INC.
		 	HRC ENERGY RESOURCES (LAFOURCHE), INC.
		 	HALCÓN FIELD SERVICES, LLC
		 	 HALCÓN LOUISIANA OPERATING, L.P.
 G3 ENERGY, LLC
 G3 OPERATING, LLC

WESTERN STAR DRILLING COMPANY
 SOUTHERN
BAY ENERGY, LLC
 SOUTHERN BAY OPERATING, L.L.C.
 SOUTHERN BAY LOUISIANA, L.L.C.
 CATENA OIL & GAS, LLC

AROC (TEXAS), INC.
 HALCON WILLISTON I,
LLC
 HALCON WILLISTON II, LLC

			
		 	By:	 	 /s/ Mark J. Mize

		 		 	Name:	 	Mark J. Mize
		 		 	Title:	 	Executive Vice President, Chief Financial Officer and Treasurer, for and on behalf of each of the foregoing Guarantors

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	 ADMINISTRATIVE AGENT
 AND
LENDER:
	  	 JPMORGAN CHASE BANK, N.A.,
 as Administrative Agent and Lender

			
		  	By:	  	 /s/ Ronald Dierker

		  		  	Name:	 	Ronald Dierker
		  		  	Title:	 	Managing Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	  	 WELLS FARGO BANK, N.A.,
 as Lender

			
		  	By:	  	 /s/ Todd C. Fogle

		  		  	Name:	 	Todd C. Fogle
		  		  	Title:	 	Vice President

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	  	 BMO HARRIS FINANCING, INC.,
 as Lender

			
		  	By:	  	 /s/ James V. Ducote

		  		  	Name:	 	James V. Ducote
		  		  	Title:	 	Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	  	 BARCLAYS BANK PLC,
 as Lender

			
		  	By:	  	 /s/ Sreedhar R. Kona

		  		  	Name:	 	Sreedhar R. Kona
		  		  	Title:	 	Assistant Vice President

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	  	 SUNTRUST BANK,
 as Lender

			
		  	By:	  	 /s/ Yann Pirio

		  		  	Name:	 	Yann Pirio
		  		  	Title:	 	Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 CAPITAL ONE, N.A.,
 as Lender

			
		 	By:	  	 /s/ Matthew Molero

		 		  	Name: Matthew Molero
		 		  	Title: Vice President

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 GOLDMAN SACHS BANK USA,
 as Lender

			
		 	By:	  	 /s/ Michelle Latzoni

		 		  	Name: Michelle Latzoni
		 		  	Title: Authorized Signatory

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 ROYAL BANK OF CANADA,
 as Lender

			
		 	By:	  	 /s/ Jay T. Sartain

		 		  	Name: Jay T. Sartain
		 		  	Title: Authorized Signatory

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 BANK OF AMERICA, N.A.,
 as Lender

			
		 	By:	  	 /s/ Adam H. Fey

		 		  	Name: Adam H. Fey
		 		  	Title: Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 THE ROYAL BANK OF SCOTLAND PLC,
 as Lender

			
		 	By:	  	 /s/ Sanjay Remond

		 		  	Name: Sanjay Remond
		 		  	Title: Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, 
 as Lender

			
		 	By:	  	 /s/ Ting Lee

		 		  	Name: Ting Lee
		 		  	Title: Director
			
		 	By:	  	 /s/ Sharada Manne

		 		  	Name: Sharada Manne
		 		  	Title: Managing Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	 		 	 NATIXIS,
 as
Lender

				
		 		 	By:	 	/s/ Louis P. Laville
		 		 		 	Name: Louis P. Laville
		 		 		 	Title: Managing Director
				
		 		 	By:	 	/s/ Timothy L. Polvado
		 		 		 	Name: Timothy L. Polvado
		 		 		 	Title: Senior Managing Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	 		 	 ING CAPITAL LLC,
 as Lender

				
		 		 	By:	 	/s/ Charles Hall
		 		 		 	Name: Charles Hall
		 		 		 	Title: Managing Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	 		 	 COMERICA BANK,
 as Lender

				
		 		 	By:	 	/s/ Justin Crawford
		 		 		 	Name: Justin Crawford
		 		 		 	Title: Senior Vice President

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	 		 	 DEUTSCHE BANK TRUST COMPANY OF AMERICAS,
 as Lender

				
		 		 	By:	 	/s/ Kevin Chichester
		 		 		 	Name: Kevin Chichester
		 		 		 	Title: Director
				
		 		 	By:	 	/s/ Eric Pratt
		 		 		 	Name: Eric Pratt
		 		 		 	Title: Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	 		 	 AMEGY BANK N.A.,
 as Lender

				
		 		 	By:	 	/s/ Charles Patterson
		 		 		 	Name: Charles Patterson
		 		 		 	Title: Senior Vice President

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

					
	LENDER:	 	 THE BANK OF NOVA SCOTIA,
 as Lender

			
		 	By:	 	/s/ Terry Donovan
		 		 	 Name: Terry Donovan
 Title:
Managing Director

  
 [SIGNATURE PAGE – 2ND AMENDMENT] 

							
	LENDER:	 		 	 KEYBANK NATIONAL ASSOCIATION
 as Lender

				
		 		 	By:	 	/s/ Chulley Bogle
		 		 		 	Name: Chulley Bogle
		 		 		 	Title: Vice President

  
 [SIGNATURE PAGE – 2ND AMENDMENT]First Amendment to Research and Distribution Agreement

 Exhibit 10.1 
 FIRST AMENDMENT TO RESEARCH AND DISTRIBUTION AGREEMENT 
 This FIRST
AMENDMENT TO RESEARCH AND DISTRIBUTION AGREEMENT is dated as of January 26, 2013 is by and between Delcath Systems, Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A. and having offices at 810
Seventh Avenue, 35th Floor, New York, New York 10019,
U.S.A. (“Delcath”) and CHI-FU Trading Co., Ltd., a corporation organized and existing under the laws of Taiwan, and having offices at 69, Lane 77, Xin Ai Road, 7th Floor, Neihu District, Taipei, Taiwan 114 (“Distributor”). 

RECITALS 
 WHEREAS, Delcath and
Distributor entered into a Research and Distribution Agreement dated February 9, 2010 (the “Agreement”); and 
 WHEREAS, the
parties now desire to amend the Agreement. 
 TERMS 
 NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Delcath and Distributor agree as follows: 

 

	 	1.	All references to “the Delcath Percutaneous Hepatic Perfusion SystemTM” are hereby changed to “the Delcath Hepatic CHEMOSAT® Delivery
System.” 

  

	 	2.	All references to the “PHP System” are hereby changed to the “CHEMOSAT System.” 

Amendment to Section 1 
  

	 	3.	Section 1 (I) “PHP System” is hereby deleted in its entirety and replaced by the following: “CHEMOSAT System” shall mean the Delcath
Hepatic CHEMOSAT Delivery System to deliver and filter melphalan hydrochloride.” 

  

	 	4.	In Section 1(e) the phrase “United States” is hereby added before the word “FDA.” 

Amendment to Section 2 
  

	 	5.	The following language is added to the first paragraph of Section 2 as a new second sentence: “The first clinical study of the CHEMOSAT System will focus on
HCC (as defined in Section 2 (d) below) (“Initial Study”).” 

  

	 	6.	The following language is added to the end of section 2(c): “Delcath has the right, but not the obligation, to perform in person visits to each site selected by
Distributor for inclusion in the Research, and shall have the right to disqualify such sites or to require modifications to such sites.” 

  

					
	Chi-Fu Amendment	 	1	 	

	 	7.	Section 2(d) is hereby deleted in its entirety and is replaced by the following: 

“The Research will be conducted in accordance with clinical protocol(s) which will be created by Delcath. The initial clinical
protocol will focus on hepatocellular carcinoma (“HCC,” also known as malignant hepatoma) and will be sent by Delcath to Distributor within thirty (30) days of the Effective Date of the First Amendment to Research and Distribution
Agreement (the “Initial Protocol”). Delcath will seek FDA approval of the clinical protocol(s), if such approval is necessary in Delcath’s sole discretion. The Research will be conducted in accordance with the following: (a) all
Applicable Laws, rules and regulations, including but not limited to statutes and regulations pertaining to the protection of human subjects in medical research in the Territory; and (b) all standards applicable in the United States for the
conduct of medical research involving human subjects. Delcath shall have the right, but not the obligation, to retain scientific advisors to review the results of the Research to determine, amongst other things, whether the results are clinically
adequate.” 
  

	 	8.	In Section 2 (g) the word “Research” is hereby deleted and replaced with “Initial Study.” 

Amendment to Section 3 
  

	 	9.	The following language is hereby deleted from section 3(b): “Promptly after Delcath’s receipt of FDA Approval.” The following language is hereby added to
the end of section 3(b): “Delcath also agrees to provide to Distributor within thirty (30) days of Distributor’s written request, copies of any documentation in Delcath’s possession which is reasonably required by Distributor for
its application to the Taiwan FDA for approval, notwithstanding whether Delcath has yet received FDA approval.” In addition, the sentence “Distributor is expected to obtain Taiwan FDA Approval within twenty four (24) months of
Delcath’s receipt of FDA Approval” is hereby deleted and is replaced with the following: “Distributor is expected to obtain Taiwan FDA Approval within thirty six (36) months of Delcath’s receipt of CE Mark approval of its
Generation 2, high-efficiency melphalan filter system.” 

  

	 	10.	The phrase “FDA Approval” is hereby deleted from section 3(d) following the phrase “within twenty four (24) months of Delcath’s receipt
of.” The following language is hereby inserted in its place: “CE Mark approval of its Generation 2, high-efficiency melphalan filter system.” 

  

					
	Chi-Fu Amendment	 	2	 	

	 	11.	Section 3(h) is hereby deleted in its entirety and is hereby replaced with the following: 

“All clinical and other test protocols for the CHEMOSAT System shall be subject to prior written approval by Delcath before testing
is undertaken; on an annual basis, Distributor shall provide Delcath with requested data and information from such tests with a cut-off date no more than sixty (60) days prior to the anniversary date of the first use by Distributor of the
CHEMOSAT System in the Territory. The report shall be submitted to Delcath no more than thirty (30) days after the anniversary date of the first use by Distributor of the CHEMOSAT System in the Territory.” 

 

	 	12.	The following language is hereby added to the end of section 3(i): “Delcath shall have the right to review these data documents at any of the clinical sites
involved in the Research.” 

 Amendment to Section 4 

 

	 	13.	A new Section 4(d)(vii) is hereby added as follows: “attend and provide support for the CHEMOSAT System at appropriate medical trade shows and congresses each
year in the Territory at Distributor’s sole expense and as agreed upon by Delcath and the Distributor, including, without limitation, relevant national and international medical trade shows and congresses with a suitable booth displaying the
CHEMOSAT System; and” 

  

	 	14.	A new Section 4(e) is hereby added as follows: “In case Delcath has reason to believe that CHEMOSAT Systems are actively resold it may require Delcath’s
independent accountant to verify the administration of the Distributor in this respect and to report to Delcath. The Distributor shall fully cooperate to provide the information requested by the independent accountant;”

  

	 	15.	A new section 4(f) is hereby added as follows: 

 “Prior to any CHEMOSAT System being shipped by Distributor to an end-user customer, each end-user customer in the Territory must successfully complete a training course including didactic training
and either proctoring by a certified proctor team or by a certified preceptorship team. The certified training course must be approved by Delcath and comply with all Applicable Laws and Government Approvals. Distributor understands and agrees that
each end-user must 

  

					
	Chi-Fu Amendment	 	3	 	

 
successfully complete the training course and be certified by the proctor or preceptorship team in order to purchase, receive and use the CHEMOSAT System, except that Distributor may ship initial
training CHEMOSAT Systems to the end user customer for the sole purpose of initial training (and identify the CHEMOSAT System and advise the end user customer accordingly).” 

 

	 	16.	A new Section 4(g) is hereby added as follows: “Delcath will provide the process for training and certifying end user customers to Distributor as may be
amended from time to time by Delcath in its sole and absolute discretion. Distributor shall comply with this process at all times.” 

  

	 	17.	A new Section 4(h) is hereby added as follows: 

 “Distributor may appoint dealers, sub-distributors, agents or sub-contractors (“collectively, the Agents”) to support the distribution of the CHEMOSAT Systems in the Territory, provided,
that Distributor shall ensure that each such Agent complies with the terms and conditions of this Agreement and further provided, that Distributor shall be responsible for any and all actions or inactions of each Agent it so appoints and shall
indemnify, defend and hold, Delcath and its officers, directors and employees, harmless from and against any and all claims, actions, suits or loss arising out of or related to the actions or inactions of any Agent. Prior to Distributor appointing
any Agent, it shall provide written notice to Delcath at least ten (10) days in advance of such appointment and provide the complete name and address and sufficient detail of the proposed scope of services to be provided by each Agent. If
Delcath requests a change of Agent, either before or after an appointment, then Distributor will use its reasonable efforts to change such Agent, if reasonably practical.” 
 Amendment to Section 5 
  

	 	18.	The following language is added to the end of section 5(a): “for services rendered related to the development of a high efficiency CHEMOSAT System capable of
receiving the CE Mark.” 

  

	 	19.	The following language is hereby deleted from section 5(b): “Delcath’s receipt of CE Approval of the PHP System.” The following language is added in its
place: “enrollment by Distributor of the first patient in a Taiwan FDA approved Initial Study.” The following language is also added to the end of section 5(b): “for services rendered in preparation of said clinical study, including
but not limited to protocol development, physician training and site evaluation.” 

  

					
	Chi-Fu Amendment	 	4	 	

	 	20.	The following language is hereby deleted from section 5(c): “Within thirty (30) days of Delcath’s receipt of FDA Approval.” The following language
is hereby added in its place: “Within thirty (30) days of the earlier of: (a) Delcath’s receipt of FDA Approval of the CHEMOSAT System; or (b) either party’s receipt of Taiwan FDA Approval of the CHEMOSAT System.”
The following language is also added to the end of section 5(c): “so long as there has been at least one (1) subject enrolled by Distributor in a Taiwan FDA approved Initial Study for use of the CHEMOSAT System, provided, that if one
subject has not been enrolled at the time of receipt of FDA or Taiwan FDA Approval, the milestone payment as set forth in this Section 5 (c) shall be made within thirty (30) days of the first subject enrolled in the Initial
Study.” 

 Amendment to Section 7 

 

	 	21.	Section 7(c) is hereby deleted in its entirety and is replaced by the following: “The Singapore Option may be exercised by providing written notice to
Delcath, no later than ninety (90) days after receipt of regulatory approval in Singapore.” 

Amendment to Section 8 
  

	 	22.	The following language is hereby deleted from Section 8: “the Effective Date of this Agreement.” The following language is inserted in its place:
“the receipt of Taiwan FDA Approval of the use of the CHEMOSAT System.” 

 Amendment to Section 9

  

	 	23.	The following language is hereby deleted from Section 9: “the Effective Date of this Agreement.” The following language is inserted in its place:
“the receipt of Taiwan FDA Approval of the use of CHEMOSAT System.” 

 Amendment to Section 10

  

	 	24.	A new Section 10(f) is hereby added as follows: “Delcath will endeavour to meet the requested delivery date but Distributor acknowledges that Delcath cannot
guarantee delivery dates for any CHEMOSAT Systems, and Distributor agrees that failure to meet any delivery date shall not constitute a breach of this Agreement or any accepted order.” 

  

					
	Chi-Fu Amendment	 	5	 	

 Amendment to Section 18 

 

	 	25.	A new Section 18(i) is hereby added as follows: 

 “Distributor hereby represents, warrants and covenants to Delcath that (a) it has and will comply with the United States’ Foreign Corrupt Practices Act, as amended, and (b) neither it,
nor any of its agents has, and covenants and agrees that neither it, nor any of its agents will, in connection with the transactions contemplated by this Agreement or in connection with any other business transactions involving Delcath, make, offer
to make or promise to make any payment or transfer anything of value, directly or indirectly: (i) to any Foreign Official (as defined below) or to an intermediary for payment to any Foreign Official; (ii) to any political party;
(iii) to any officer, director or employee, of any actual or potential customer of Distributor; (iv) to any officer, director or employee of Delcath or any of its affiliates; or (v) to any other person or entity, if such payment or
transfer would violate the laws of the country in which the transfer is made or the laws of the United States, including without limitation the Foreign Corrupt Practices Act, as amended. It is the intent of the parties that no payments or transfers
of value shall be made which have the purpose or effect of public commercial bribery, acceptance or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining business. This Section 18(i) shall not, however, prohibit
normal and customary business entertainment or the giving of business mementos of nominal value in connection with Distributor’s performance under the Agreement. Distributor also hereby represents, warrants and covenants to Delcath that neither
it, nor any of its agents, nor any of their owners, officers, directors, or employees, is a Foreign Official. For purposes of this Agreement, the term “Foreign Official” shall include: (i) any officer or employee of the government of
any foreign (i.e., non-U.S.) nation or any federal, regional or local department, agency, state-owned enterprise or corporation or other instrumentality thereof; (ii) any employee or official of a public international organizational
(iii) any person acting in an official capacity for or on behalf of any of such entities identified in clauses (i) or (ii); and (iv) any official of a political party, or candidate or nominee of any political party in any foreign
(i.e., non-U.S.) nation.” 
  

	 	26.	A new Section 18(j) is hereby added as follows: 

 “Distributor agrees to comply with all Applicable Laws including without limitation economic sanctions and export control laws and regulations of the United States of America. 

  

					
	Chi-Fu Amendment	 	6	 	

 Without limiting the foregoing, Distributor shall not, directly or indirectly,
(i) export, re-export, or otherwise dispose of any items received in connection with this Agreement to any person, entity, or destination, or for any use, prohibited under Applicable Laws, without obtaining prior authorization from Delcath, or
(ii) engage in transactions with or make any payment to any unauthorized person or entity designated in Applicable Laws. Distributor’s breach of this provision shall constitute cause for immediate termination of this Agreement. Distributor
agrees to indemnify and hold harmless Delcath for Distributor’s noncompliance with such laws or regulations. This provision shall survive termination or cancellation of this Agreement.” 

 

	 	27.	A new Section 18(k) is hereby added as follows: “Distributor shall complete and send to Delcath an Export Control and Anti-Corruption Compliance Certificate
in the form attached hereto as Exhibit A on an annual basis within thirty (30) days of its receipt of Delcath’s written request. Delcath shall be entitled to terminate this Agreement immediately in the event of any violation or breach of
this Section 18(k) by Distributor.” 

 Amendment to Section 19 

 

	 	28.	A new Section 19(e) is hereby added as follows: 

 “All intellectual property rights, whether existing as of the date of this Agreement or in the future, relating to Delcath, its business, the CHEMOSAT System and this Agreement, including, without
limitation, all names, trademarks, copyrights, patents, mask works, trade secrets, know-how, technology, data, designs, specifications, materials, processes, computer software and related documentation and source code and other intellectual property
rights (“Delcath Intellectual Property”), are and shall remain the exclusive property of Delcath and nothing in this Agreement shall be deemed to transfer or grant to Distributor a license or other right to use Delcath Intellectual
Property, except as expressly provided in this Agreement. Distributor agrees that it shall not, either during the Term or at any time thereafter, reverse engineer or copy the CHEMOSAT System or Delcath Intellectual Property or otherwise use or
infringe upon Delcath’s Intellectual Property. Upon the termination or expiration of this Agreement, Distributor shall immediately discontinue all use of all Delcath Intellectual Property. Distributor shall immediately notify Delcath if it
becomes aware of any infringement, potential infringement 

  

					
	Chi-Fu Amendment	 	7	 	

 
or misappropriation of any Delcath Intellectual Property and shall cooperate with Delcath in any action taken to protect or enforce any of its Delcath Intellectual Property rights. Any
intellectual property which Distributor and any of its employees, officers, agents and directors may develop, either alone or jointly, in the course of performing its duties under this Agreement and which relates to the CHEMOSAT System or business
of Delcath shall be the property of Delcath and is hereby transferred and assigned to Delcath without any additional compensation, payment or royalty. Distributor shall cooperate in the transfer and assignment of any such intellectual property and
shall execute all documents and papers necessary to effectuate the transfer and assignment of such intellectual property to Delcath.” 
 Amendment to Section 27 
  

	 	29.	Delcath’s address in section 27(b) is hereby amended to read as follows: 

 Delcath Systems, Inc. 
 Attention: Eamonn P. Hobbs 

810 Seventh Avenue, 35th Floor 
 New York, NY 10019 
 Amendment to Section 30 

 

	 	30.	Section 30 is hereby amended to add sections 4(e), 4(h), 18(j) and 19(e) to the list of sections of the Agreement surviving the expiration or termination of the
Agreement. 

 Amendment to Section 34 

 

	 	31.	A new Section 34 is hereby added as follows: 

 “Force Majeure. Any non-performance by either party (other than the payment of money) shall be excused to the extent that performance is rendered impossible or commercially impracticable by
fire, flood, hurricane, typhoon, earthquake, war, acts of terrorism, riots, governmental acts or orders or restrictions, strikes, lockouts, failures of suppliers or any other reason where failure to perform is beyond the reasonable control of, and
is not caused by the acts, decisions, negligence or willful misconduct of, the non-performing party. A party that would be in breach of this Agreement but for the presence of this Section 34 (the “Affected Party”) shall use its best
efforts to remove, remedy 

  

					
	Chi-Fu Amendment	 	8	 	

 
or eliminate (as applicable) the condition or event that resulted in the application of this Section 34. If the Affected Party is unable to do so within sixty (60) days to the
reasonable satisfaction of the other party, then the other party shall be entitled to terminate this Agreement upon ten (10) business days notice.” 
 Amendment to Exhibit A 
  

	 	32.	A new Exhibit A is hereby added to the Agreement in the form attached hereto as Exhibit 1. 

 

	 	33.	Except as modified herein, the Agreement remains in full force and effect. 

 

	 	34.	This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but all of which together will constitute one and the same
agreement. Delivery of an executed counterpart by facsimile or by electronic transmission shall be as effective as delivery of a manually signed counterpart. 

 IN WITNESS WHEREOF, Delcath and Distributor have caused this First Amendment to Research and Distribution Agreement to be executed by their respective authorized representatives to be effective as of the
date first written above. 
  

			
	DELCATH SYSTEMS, INC.
		
	By:	 	

	 	  

	Name:	 	Agustin Gago
	Title:	 	Executive Vice President, International Operations
	
	CHI-FU TRADING CO., LTD.
		
	By:	 	

	 	  

	Name:	 	Wayne Hsu
	Title:	 	Managing Director

  

					
	Chi-Fu Amendment	 	9	 	

 EXHIBIT A 
 EXPORT CONTROL AND ANTI-CORRUPTION COMPLIANCE CERTIFICATE 
 Delcath Systems, Inc.
(“Delcath”) and CHI-FU Trading Co., Ltd. (“Distributor”) entered into that certain exclusive distribution agreement dated February 9, 2010 (“Research and Distribution Agreement”). 

I,
                                        , the
duly appointed
                                         for the
Distributor do herby certify on behalf of the Distributor, that the Distributor and each employee and agent (i) has complied with sections 18(i), 18(j) and 18(k) of the Research and Distribution Agreement, (ii) is not aware of any actions
which are in violation of sections 18(i), 18(j) or 18(k) and (iii) will continue to comply with the provisions of sections 18(i), 18(j) or 18(k). 
  

			
	CHI-FU Trading Co., Ltd.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	Date:	 	  

  

					
	Chi-Fu Amendment	 	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]